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In dialyzed patients, preservation of residual renal function is
associated with better survival, lower morbidity, and greater
quality of life. To analyze the evolution of residual diuresis
over time, we prospectively monitored urine output in 401
pediatric patients in the global IPPN registry who
commenced peritoneal dialysis (PD) with significant residual
renal function. Associations of patient characteristics and
time-variant covariates with daily urine output and the risk of
developing oligoanuria (under 100ml/m2/day) were analyzed
by mixed linear modeling and Cox regression analysis
including time-varying covariates. With an average loss of
daily urine volume of 130ml/m2 per year, median time to
oligoanuria was 48 months. Residual diuresis significantly
subsided more rapidly in children with glomerulopathies,
lower diuresis at start of PD, high ultrafiltration volume, and
icodextrin use. Administration of diuretics significantly
reduced oligoanuria risk, whereas the prescription of
renin–angiotensin system antagonists significantly increased
the risk oligoanuria. Urine output on PD was significantly
associated in a negative manner with glomerulopathies
(−584ml/m2) and marginally with the use of icodextrin
(−179ml/m2) but positively associated with the use of
biocompatible PD fluid (+111ml/m2). Children in both Asia
and North America had consistently lower urine output
compared with those in Europe perhaps due to regional
variances in therapy. Thus, in children undergoing PD,
residual renal function depends strongly on the cause of
underlying kidney disease and may be modifiable by diuretic
therapy, peritoneal ultrafiltration, and choice of PD fluid.
Kidney International (2015) 88, 605–613; doi:10.1038/ki.2015.108;
published online 15 April 2015
KEYWORDS: children; oligoanuria; peritoneal dialysis; registry; risk factors; urine
volume
Chronic dialysis is associated with high patient morbidity and
mortality. Outcome studies suggest that residual renal
function (RRF) is a more important determinant of patient
survival, morbidity, and quality of life than the prescribed or
achieved dialysis dose.1–3 As RRF is generally considered a
largely unmodifiable and rapidly diminishing fraction of fluid
and solute clearance in dialyzed patients, a limited body of
research has explored its determinants and amenability to
therapeutic intervention. These studies have suggested a
major impact of the underlying renal disease,4–8 baseline
RRF5,9, and dialysis modality,9–12 with possible additional
effects of ethnicity,4 gender,4,13 obesity,13–15 medica-
tions,4,14,16,17 infections,13,18 cardiovascular events,19 and
dialysis biocompatibility.20
RRF appears to be particularly important in dialyzed
children, where it has been associated with better nutritional
status and growth, cardiovascular function, and survival.21–24
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Congenital anomalies of kidney and urinary tract (CAKUT)
are the leading cause of end-stage renal disease (ESRD) in
children, and these disorders are typically characterized by the
preservation of high urine output even in CKD stage V. In
addition, peritoneal dialysis (PD), which tends to preserve
RRF better than hemodialysis,4,9,25–27 is the dialysis modality
of first choice in children.
Although the pediatric chronic peritoneal dialysis (CPD)
population might be particularly well suited to study under-
lying conditions and therapeutic measures influencing RRF,
the low incidence of pediatric ESRD has so far precluded large
prospective studies assessing the course of RRF in children
commencing chronic dialysis. To overcome this challenge, we
interrogated the global IPPN Registry, a comprehensive
prospective database encompassing more than 2000 pediatric
patients undergoing CPD in 40 countries around the globe.28
We identified 401 children who commenced CPD with
significant RRF and analyzed the factors associated with the
evolution of residual diuresis over time.
RESULTS
Cohort selection and patient characteristics
The selection of the study cohort from the IPPN registry
population is described in Figure 1. Between April 2007 and
June 2013, 2134 pediatric CPD patients were enrolled at 100
pediatric dialysis centers in 39 countries. Among 1829
patients with valid information on daily urine volume, 757
patients were incident with diuresis information reported
within 3 months of CPD initiation. Of these, 161 patients
were excluded because of oligoanuria (defined by daily urine
output ≤ 100 ml/m2 body surface area) at the start of CPD. Of
the remaining 596 patients, 185 children with only a single
urine volume measurement and 10 patients in whom urine
output decreased transiently were excluded, leaving 401
children for analysis. The cohort was largely representative
of the total IPPN cohort and the pediatric PD population, as
reported to population-based registries in Europe and the
United States (Supplementary Table S-1 online).
The characteristics of the study cohort are given in Table 1
and Supplementary Table S-2 online. The median duration of
follow-up was 17 (IQR: 10–27) months. Among the 401 patients,
299 exhibited preserved diuresis during follow-up, whereas
102 developed oligoanuria. The most common primary renal
diagnosis was CAKUT (50%), followed by glomerulopathies
(30%). Children with CAKUT had higher urine output at PD
start than patients with glomerulopathies (1.26± 0.71 vs.
0.77± 0.52 l/m2/day), whereas eGFR tended to be lower in
CAKUT patients (9.0± 4.5 vs.10.2± 5.5 ml/min/1.73 m2).
In 180 of the 401 patients, the results of 603 twenty-four-
hour urine and dialysate collections were available for analysis.
Information on the peritoneal transport status obtained from
Peritoneal Equilibration Tests was available in 200 subjects.
Determinants of residual diuresis
The univariate exploration of factors potentially associated
with progressive loss of residual diuresis is given in Table 1.
Relative to the children who became oligoanuric during the
observation period, children who retained diuresis frequently
had CAKUT as underlying renal disease, exhibited a larger
urine output at the time of PD initiation, were exposed to
lower dialysate glucose and less frequently to icodextrin, and
achieved lower daily ultrafiltration rates (Table 1). They
showed a lower degree of estimated fluid excess, lower blood
pressure, and were administered less antihypertensive agents
including renin–angiotensin system (RAS) antagonists. In
contrast, patients with stable versus vanishing diuresis did not
differ by age, ethnicity, body mass index, PD treatment
modality, total PD fluid turnover, dialytic clearance, the use of
biocompatible PD fluid or of diuretics, peritonitis frequency,
and the cumulative exposure to nephrotoxic drugs (amino-
glycosides and glycopeptides). The duration of follow-up was
longer in patients who became oligoanuric than in those with
stable diuresis (20.8 (IQR: 12.8–31.8) vs. 15.4 (8.8–25.5)
months, P= 0.001).
Cox regression analysis was performed to identify
independent risk factors of progression to oligoanuria,
including time-variant covariates (Table 2). This analysis
confirmed an almost fourfold higher risk of oligoanuria in
patients with glomerulopathic disorders relative to those with
CAKUT (Po0.0001). The corresponding Kaplan–Meier
survival analysis of residual diuresis revealed significantly
earlier loss of urine volume in patients with glomerulopathies
2134 Patients in registry
305 missing urine output information
1829 with valid
urine output information
1072 prevalent on PD at registry entry
161 with baseline urine output
 < 100 ml/m2 per day
596 with baseline urine output
≥ 100 ml/m2 per day
757 incident patients
with urine output information
within 3 months after starting PD
185 only initial urine output available
10 with transient oliguria
401 patients with follow-up
urine information
Figure 1 | Selection of study subjects. PD, peritoneal dialysis.
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(Po0.0001, Figure 2). It was also demonstrated that a
high initial residual urine volume lowers oligoanuria risk
independently of the kidney disease type (Po0.0001),
although the annual loss of daily urine output was slightly
more pronounced in patients with higher initial urine output
(Figure 3). Interestingly, initial urine output was not
replaceable by eGFR in predicting the oligoanuria risk. In
addition, the use of icodextrin (P= 0.001) and higher
achieved ultrafiltration rates (P= 0.002) were significant risk
factors of oligoanuria. After adjusting for the underlying
disease type, baseline urine output, and dialytic fluid removal,
treatment with diuretics was associated with an 82% oligo-
anuria risk reduction during the observation period (P= 0.004).
The diuresis survival curves of children with and without
diuretic therapy from the start of PD are shown in Figure 4.
Conversely, the use of RAS antagonists tended to increase the
risk of becoming oligoanuric (P= 0.04). Body mass index, PD
modality, and the number of peritonitis episodes did not
affect the oligoanuria risk. The observed associations were
independent of the region of residence.
Table 1 |Patient characteristics, stratified according to prospective evolution of diuresis
All Preserved diuresis Oligoanuria during follow-up P-value
N 401 299 102
Total observation time (years) 1.26 (1.46) 1.10 (1.42) 1.55 (1.49) 0.001
Male sex 218 (54.4%) 171 (57.2%) 47 (46.1%) 0.052
Age (years) 9.6 (10.6) 9.9 (10.6) 8.6 (10.4) 0.285
Pubertal 162 (40.4%) 126 (42.1%) 36 (35.3%) 0.224
Ethnicity
Caucasian 246 (61.3%) 186 (62.2%) 60 (58.8%) 0.545
Other 155 (38.7%) 113 (37.8%) 42 (41.2%)
Gross national income (1,000 Intern’l $) 23.0± 11.4 22.6± 10.8 24.2± 12.8 0.216
Underlying diagnosis
CAKUT 200 (49.9%) 175 (58.5%) 25 (24.5%) o0.001
Glomerulopathies 122 (30.4%) 67 (22.4%) 55 (53.9%)
Other 79 (19.7%) 57 (19.1%) 22 (21.6%)
BMI s.d. scores − 0.26±1.43 − 0.23±1.45 − 0.36±1.37 0.422
Δ Height s.d. scores per year − 0.03±0.96 0.01±0.90 − 0.16±1.08 0.106
Estimated fluid excess (%) 1.34± 2.43 1.07±2.01 2.12±3.26 0.003
Blood pressure s.d. scores
Systolic 1.02± 1.39 0.85±1.28 1.51±1.56 o0.001
Diastolic 0.92± 1.33 0.84±1.22 1.17±1.59 0.063
Medications
≥ 2 Antihypertensive drugs 125 (31.2%) 76 (25.4%) 49 (48.0%) o0.001
RAS antagonist 129 (39.2%) 82 (33.5%) 47 (56.0%) o0.001
Diuretics 85 (25.8%) 63 (25.7%) 22 (26.2%) 0.931
Urine output (l/m2 per day) 1.00± 0.63 1.11±0.69 0.67±0.48 o0.001
Urinary GFR (ml/min/1.73m2)a 5.2± 5.0 5.9± 5.2 2.8 ± 3.2 o0.001
Weekly Kt/V ureaa
Urinary 1.55± 2.13 1.77±2.31 0.84±1.13 0.004
Dialytic 1.97± 2.28 1.89±2.56 2.22±0.96 0.320
Total 3.48± 4.02 3.63±4.54 3.01±1.45 0.294
PD modality
CAPD 97 (24.2%) 71 (23.7%) 26 (25.5%) 0.375
NIPD (APD with dry day) 188 (46.9%) 146 (48.8%) 42 (41.2%)
CCPD (APD with wet day) 116 (28.9%) 82 (27.4%) 34 (33.3%)
PD fluids
Biocompatible PD fluid 171 (42.6%) 125 (41.8%) 46 (45.1%) 0.562
Icodextrin 32 (8.0%) 18 (6.0%) 14 (13.7%) 0.013
Glucose exposure (g/kg per day) 3.56± 2.07 3.37±1.99 4.11±2.20 0.002
Total PD fluid turnover(l/m2 per day) 5.53± 2.67 5.43±2.65 5.83±2.72 0.199
Ultrafiltration volume (l/m2 per day) 0.43± 0.33 0.38±0.29 0.59±0.39 o0.001
Patients with 41 peritonitis 142 (35.4%) 101 (33.8%) 41 (40.2%) 0.242
Exposure to nephrotoxic drugs (days) 0.8 ± 4.5 1.0± 5.4 0.2 ± 1.5 0.428
Abbreviations: APD, automated peritoneal dialysis; BMI, body mass index; CAKUT, congenital anomalies of kidney and urinary tract; CAPD, continuous ambulatory peritoneal
dialysis; CCPD, continuous cycling peritoneal dialysis; GFR, glomerular filtration rate; NIPD, nocturnal intermittent peritoneal dialysis; PD, peritoneal dialysis; RAS, renin–
angiotensin system. Data are given as N (%), mean± s.d., or median (interquartile range). P values denote significant differences between patients with retained diuresis and
those progressing to oligoanuria.
aMeasured in 180 patients.
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A separate proportionate hazard analysis was performed
for the subgroup of patients with available Peritoneal
Equilibration Test information. The hazard ratio to turn
oligoanuric did not differ between patients with low, low-
average, high-average, and high transporter status (overall
P= 0.487).
In addition to the extended Cox regression analysis of the
oligoanuria risk performed on the entire cohort, we utilized
mixed linear modeling to identify factors predicting residual
urine volume at any time on PD as a continuous variable in
those 180 patients in whom precise urine volume measure-
ments from 24-h urine collections were available (Table 3).
All factors significantly associated with the development of
oligoanuria (Table 1) were offered for inclusion in the model.
A strong linear trend toward lower diuresis with time on
dialysis was observed (Po0.0001); a mean annual loss of 138
(95% confidence interval: 92 to 184) ml/m2 residual urine
volume was calculated by univariate regression for the
population as a whole (Table 3, Model 1). Independently of
time on dialysis, the diagnosis of glomerulopathy or other
non-CAKUT disease and the use of icodextrin were associated
with lower urine output, whereas the use of biocompatible PD
fluids and, at borderline significance, diuretics positively
predicted residual urine volume. As some factors such as PD
duration and the use of biocompatible PD fluid, icodextrin,
and diuretics strongly differed by region (see Supplementary
Table S-1 online), another model including the region of
residence was calculated (Table 3, Model 2). This analysis
disclosed that patients in the United States, Turkey, and Asia
Table 2 | Extended Cox regression analysis of factors predicting risk of developing oligoanuria
Full model Reduced model
HR (95% CI) P-value HR (95% CI) P-value
Male sex 0.961 (0.616–1.498) 0.861
Age at initiation of PD (year) 0.953 (0.899–1.011) 0.112 0.953 (0.914–0.992) 0.026
Puberty 0.918 (0.503–1.654) 0.777
BMI s.d. scores 1.148 (0.952–1.391) 0.153 1.154 (0.965–1.386) 0.121
Estimated fluid excess (%) 1.102 (1.006–1.200) 0.030 1.080 (0.993–1.163) 0.056
Systolic blood pressure s.d. scores 0.963 (0.834–1.109) 0.606
Underlying diagnosis (reference: CAKUT)
Glomerulopathies 4.134 (2.339–7.527) o.0001 4.776 (2.791–8.467) o0.0001
Other 2.160 (1.012–4.541) 0.043 2.607 (1.272–5.238) 0.015
Initial urine output (l/m2 per day) 0.470 (0.285–0.743) 0.002 0.441 (0.278–0.672) o0.0001
Medications
RAS antagonists 1.603 (0.979–2.631) 0.061 1.546 (1.018–2.346) 0.040
Diuretics 0.170 (0.041–0.475) 0.003 0.178 (0.043–0.486) 0.004
PD modality (reference: CAPD)
NIPD 0.974 (0.422–2.406) 0.952
CCPD 0.861 (0.407–1.990) 0.714
PD fluids
Biocompatible PD fluid 0.881 (0.453–1.716) 0.710
Icodextrin 2.380 (1.327–4.196) 0.003 2.285 (1.364–3.699) 0.001
Ultrafiltration volume (l/m2 per day) 1.811 (1.328–2.462) o.0001 1.885 (1.253–2.120) o0.0001
No. of peritonitis episodes 0.992 (0.790–1.205) 0.937
Nephrotoxic drug exposure (days) 0.905 (0.751–1.067) 0.263
Region of residence (reference: Europe)
United States 0.928 (0.279–2.623) 0.895
Latin America 0.563 (0.230–1.349) 0.201
Turkey 0.905 (0.751–1.067) 0.263
Asia 1.050 (0.473–2.280) 0.090
Abbreviations: BMI, body mass index; CAKUT, congenital anomalies of kidney and urinary tract; CAPD, continuous ambulatory peritoneal dialysis; CCPD, continuous
cycling peritoneal dialysis; CI, confidence interval; GFR, glomerular filtration rate; HR, hazard ratio; PD, peritoneal dialysis; NIPD, nocturnal intermittent peritoneal dialysis;
RAS, renin–angiotensin system.
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Figure 2 | Survival of residual diuresis by the renal diagnosis
group.
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had consistently lower urine output than children treated in
Europe. The inclusion of region variably attenuated the effect
of diuretics, biocompatible PD fluid, and icodextrin.
DISCUSSION
Our prospective study in a large cohort of children
commencing CPD defines key determinants of residual
diuresis in the pediatric ESRD population. Among more
than 750 children starting PD, 80% still had significant urine
output. For these, the median time to oligoanuria while on
PD was 4 years. Hence, although RRF declines with time on
dialysis, a large proportion of pediatric PD patients enjoy
extended preservation of urine output.
The most important cause for the relatively slow overall
loss of residual diuresis was the high proportion (50%) of
children with underlying CAKUT. Children with these
disorders were four times less likely to develop oligoanuria
and had on average 4600 ml/m2 higher daily urine output
than children with ESRD due to glomerulopathies at any time
during the observation period. Although we cannot com-
pletely exclude the possibility of overestimated hazard ratios
due to informative censoring (e.g. renal transplantation being
a competing event), our findings are in keeping with previous
reports of glomerulopathies being a risk factor for rapid loss
of urine output in adult populations.4–8 Whereas in adult
patients diabetic nephropathy is by far the most prevalent
glomerular disease,4,7,8 hereditary podocyte disorders are the
most common type of glomerulopathy in children. Our
findings indicate that these disorders are prone to rapid loss of
RRF in a manner similar to what occurs with the acquired
glomerular diseases causing ESRD in adults.
We confirmed previous reports that high urine volume at
initiation of PD is predictive of sustained diuresis.9 It is
noteworthy that this effect was independent of the underlying
kidney disease type, suggesting that CAKUT patients maintain
diuresis on dialysis intrinsically better than children with
other kidney disorders. The effect of disease type was also
independent of blood pressure, which, as expected, was
higher in the glomerulopathic patients.
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annualized loss of residual diuresis (R2 = 0.1389, P o0.0001).
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Figure 4 | Survival of residual diuresis in 45 patients receiving
diuretic therapy compared with patients without diuretics.
Table 3 |Mixed linear model analysis of factors predicting residual urine volume
Variables Model 1 Model 2
Estimate s.e. P-value Estimate s.e. P-value
Intercept 1125 104 o0.0001 1350 106 o0.0001
Time on PD (years) − 138 23 o.0001 − 134 23.4 o0.0001
Underlying diagnosis (ref. CAKUT)
Glomerulopathies − 614 103 o0.0001 − 584 101 o0.0001
Other − 395 145 0.007 − 330 142 0.021
Use of diuretics 103 59 0.074 84 61 0.165
Use of biocompatible PD fluid 121 59 0.028 111 58 0.057
Use of icodextrin − 202 100 0.043 − 179 103 0.083
Ultrafiltration volume (l/m2 per day) − 35 23 0.138 − 42 24 0.077
Region of residence (ref: Europe)
North America − 431 215 0.047
Latin America 46 120 0.705
Turkey − 259 131 0.050
Asia −420 153 0.007
Abbreviations: CAKUT, congenital anomalies of kidney and urinary tract; PD, peritoneal dialysis.
Daily urine output per m2 body surface area was used as the dependent variable in the model. Estimates denote ml/m2 diuresis difference attributable to predictor variable
(per one unit for quantitative variables).
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It is also of note that patients with CAKUT did not have
better eGFR at the start of PD, and the lower oligoanuria risk
attributable to high urine output was not replaceable by
eGFR. Hence, the advantage of CAKUT patients is limited to
the preservation of urine output rather than small-solute
clearance.
A notable finding of this study is the positive impact of
diuretics on maintaining residual urine output. Children who
received diuretics from the initiation of PD were 80% less
likely to become oligoanuric than untreated patients. Our
findings represent the first evidence suggesting effective
stimulation of residual diuresis by diuretics in dialyzed
children. The findings of this observational study are in
keeping with the results of a randomized controlled trial in
adults on CPD in which furosemide increased urine volume
without affecting creatinine and urea clearance;29 in contrast,
another adult study observed a faster decline of residual GFR
associated with diuretic usage.30 The efficacy of diuretics is
also controversial in the adult hemodialysis population.16,31
In view of the crucial role of fluid balance in preventing
cardiovascular morbidity in the dialysis population, our
findings should stimulate interventional studies to further
evaluate the efficacy of diuretic therapy in pediatric and adult
dialysis patients.
The observed associations of higher daily ultrafiltration
rates and icodextrin use with lower urine volumes and a
higher risk of oligoanuria may reflect the efforts for enhanced
dialytic fluid removal in patients with failing RRF. However,
the observational nature of our study does not allow us to
exclude the alternative interpretation of a causative detri-
mental impact of higher ultrafiltration on residual diuresis. Of
interest in this context, in a randomized controlled trial in
adult PD patients, the use of icodextrin was associated with a
statistically insignificant but slightly more rapid loss of RRF
over time.32 In contrast, a recent systematic review concluded
that icodextrin improves peritoneal ultrafiltration without
compromising RRF or urine output.33
Several randomized clinical trials in adult PD patients
evaluated a potential effect of the use of biocompatible PD
fluids with low glucose degradation product content on the
preservation of RRF.34–38 Most studies reported better pre-
served urine output with low glucose degradation product
solutions, with a somewhat less consistent effect on small
molecule clearance. A recent meta-analysis of seven rando-
mized clinical trials encompassing 520 adult patients identi-
fied a mean difference of 126 (95% CI 27–226) ml urine
volume per day in favor of biocompatible PD fluids.20 Our
multivariate analysis of 180 children attributed a marginal
increase of daily urine volume (111± 58 ml/m2) to the use of
biocompatible PD fluids, although the risk of developing
oligoanuria was not reduced.
Blood pressure is a well-established risk factor for the loss
of renal function in pre-dialytic CKD both in adults and
children, as well as in incident adult dialysis patients.39,40
In this pediatric PD population, blood pressure was not
predictive of residual urine volume or the risk of developing
oligoanuria. Although the KDIGO clinical practice guideline
recommends RAS inhibition in CKD, few previous studies
addressed a potential effect of RAS antagonist therapy on
RRF. In 1032 incident adult PD patients followed in a
Canadian national registry, the use of ACE inhibitors was
associated with a reduced risk of RRF loss defined by urine
output o200ml per day.4 Smaller single-center studies yielded
conflicting results regarding the impact of RAS blockade on
RRF.8,17 In our pediatric study, RAS blockade did not appear
to preserve overall residual urine volume but marginally
increased the risk of developing oligoanuria. We speculate
that the pediatric PD population may be at greater risk of
episodic volume depletion compared with adults, due to a
higher incidence of gastrointestinal and febrile infections in
childhood adding to increased urinary fluid and electrolyte
losses characteristically present in patients with dysplastic
kidney disease. In this setting, RAS blocker therapy might
increase the risk of episodic renal hypoperfusion leading to
irreversible oligoanuria.
In the same context, studies performed in the 1990s
observed that frequent peritonitis episodes predisposed to a
rapid loss of RRF.18 We did not observe an association of the
number of peritonitis episodes or the duration of exposure to
nephrotoxic antibiotics with the evolution of residual diuresis.
The markedly decreased overall incidence, earlier detection,
and more efficient treatment of peritonitis accomplished
in recent years may have largely eliminated the impact of
PD-associated infections on RRF.
The estimated deviation of actual body weight from ‘dry’
weight did not predict urine volume over time and tended to
be associated with an increased oligoanuria risk. This finding
does not support the widespread notion that urine output
increases with fluid overload.
Other risk factors for RRF loss identified previously in
adult patients, i.e. male sex and obesity, were also not found
to be significant in our study. This may be explained by the
limited number of sexually mature individuals and the low
prevalence of obesity in this global pediatric population.
A potential limitation of this study concerns the general-
izability of our findings. As reporting to the IPPN Registry is
voluntary, we cannot entirely exclude selection bias related to
the type of centers reporting to the registry, the patients
reported by a particular center, and the availability of urine
output information. However, we found the study cohort to
be largely representative of the entire IPPN cohort and other
international pediatric RRT registry populations regarding the
distribution of age and eGFR at the start of PD, as well as the
underlying renal disease spectrum (Supplementary Table S-1
online). Likewise, the average follow-up time on PD was
comparable to that of the total incident patient population
and, at least for the European countries including Turkey,
matched those recently reported by the population-based
ESPN/ERA-EDTA Registry.41
Global data collection is both a strength and a limitation of
the IPPN Registry. Although studies as the one presented
here only become possible by the contribution of multiple
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pediatric dialysis centers around the globe, regional differ-
ences in PD populations and treatment practices might
influence observed outcomes. Global adjustment for region,
as performed in this study, is generally considered appro-
priate, although some residual confounding cannot be ruled
out. Indeed, we noted a lower prevalence of CAKUT in Asia,
more frequent use of diuretics, icodextrin, and biocompatible
PD fluids in Europe, and less frequent automated PD use in
Turkey. The preliminary conclusion from our multivariate
analyses is that residual urine output generally differs between
regions, but the region of residence probably does not affect
the risk of becoming oligoanuric while on PD.
In summary, in this large pediatric cohort study, we
identified that, although substantial urine output is frequently
maintained in children undergoing CPD, underlying glomer-
ulopathies and dialysis prescriptions resulting in high ultra-
filtration rates are risk factors for rapid progression to
oligoanuria. The increased volume and/or duration of urine
output associated with the use of diuretics and biocompatible
PD fluids are notable observations that might deserve
evaluation in controlled interventional trials.
MATERIALS AND METHODS
Data collection
The IPPN Registry collects information from infants, children, and
adolescents treated with CPD around the globe. Participation in the
registry is voluntary. The participating centers are asked to enroll all
prevalent and incident consenting patients and follow them until
discontinuation of PD.
Data input to the IPPN Registry is performed exclusively via an
Internet-based web platform (www.pedpd.org). Data pertaining to
basic patient and PD modality characteristics, growth and weight
gain, nutritional modalities, intercurrent hospitalizations, hematol-
ogy and serum biochemistry, medications, dialysis prescription, daily
residual urine volume and ultrafiltration, and, optionally, echocar-
diography and ambulatory blood pressure monitoring results are
submitted every 6 months. In addition, PD-related infections and
access revisions and the findings of any Peritoneal Equilibration
Tests, and renal and dialytic clearance studies are reported whenever
these are performed. Data entries are automatically checked for plausi-
bility and completeness. Data protection is ensured by de-identified
data input. The registry protocol was approved by the ethical
committees/institutional review boards as required at each partici-
pating center. Written parental consent and, whenever appropriate,
assent from patients were obtained.
Statistics
Data are expressed by absolute and relative frequencies, mean± s.d.
for normally distributed variables, and by median and interquartile
range for variables with skewed distribution.
Systolic and diastolic blood pressure was converted to s.d. scores
adjusting for age, sex, and height according to the methods published
in the NHBPEP Fourth Report.42 Residual GFR was calculated as the
mean of urinary creatinine and urea clearance.
Between-group differences were assessed by Pearson’s χ2-test, a
t-test, or the Wilcoxon rank-sum test as appropriate. Extended Cox
proportional hazard modeling was applied, incorporating time-
variant covariates and censoring patients with retained diuresis at last
observation. For the analysis of diuresis ‘survival’ by diuretic use
patients was censored when diuretics were discontinued (treatment
group) or initiated (no-treatment group). Kaplan–Meier survival
analysis with log-rank significance testing was performed to illustrate
the effect of key factors associated with preservation of urine output.
For the assessment of urine volume over time, general mixed linear
models were fitted to account for the dependent data structure
within the same patient (random intercept and slope) applying a
spatial (spherical) covariance structure based on the Akaike
information citerion. Possible covariates were included, and results
are given both for full and reduced models. The latter were
constructed by backward variable selection with a selection margin of
Po0.2. The annualized change in urine volume was calculated from
the first and the last observed value and plotted against baseline urine
volume within a regression plot including 95% prediction and
confidence bands. Data were analyzed using SAS 9.2 (SAS Institute,
Cary, NC, USA).
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